Genus Biosystems’ Focus on Quality Drives Reproducible Results in FDA MAQC Project
GenUs BioSystems has announced its participation in the FDA-sponsored "MicroArray Quality Control (MAQC)" consortium.
The results of this multi-site, landmark collaboration were published in a series of papers in a special issue of Nature Biotechnology, providing an objective comparison of several array platforms in many different laboratories.
The study underscores the importance of an intense focus on quality control processes and consistent experimental protocols due to the complexity of microarray experiments and the sensitivity of microarray technologies.
As one of three laboratories chosen by GE Healthcare to represent their array platform in this study, GenUs confirmed its ability to provide reliable gene expression data.
The CodeLink platform consistently detected a large number of genes across all three test sites.
"Gene expression experiments are complex, regardless of which platform is used," said Scott Magnuson, Ph.D., president of GenUs.
"The MAQC study demonstrates that when experienced researchers focus on quality and employ consistent methods, powerful genomic data is produced."
"GenUs and CodeLink demonstrated outstanding performance in these rigorous tests, and we are very excited about the future of microarrays in research and clinical studies."